Tracking kidney urine effects after a short pause in CF therapy
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study checks how a common cystic fibrosis (CF) medicine affects urine markers after briefly stopping it and then restarting. The goal is to better understand whether the treatment shift changes kidney-related signals in people with CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult older than 17 with cystic fibrosis
- Your kidneys are working well (eGFR above 90, a blood test measure of kidney function)
- You can understand the study and agree to participate in writing
- You do not have a serious, sudden (acute) illness right now
- Your lung health is not severely impaired (ppFEV1 is not below 40%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the kidneys work in people with cystic fibrosis, especially those taking highly effective new treatments. It aims to understand kidney function in different groups, including those who are hospitalized frequently or rarely.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.
This study measures how often people with cystic fibrosis who take elexacaftor-tezacaftor-ivacaftor (ETI) experience breathing limitations during exercise and what factors are linked to this.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.